All In Biotech

Drug Trial Radar · NCT06244485

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

210

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Nov 1, 2028

Study completion Nov 1, 2028

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Feb 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd antibody-drug conjugates (ADC) in participants with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • Valemetostat tosylateDrug

    Administered orally once daily

  • T-DXdDrug

    One IV infusion Q3W on Day 1 of each 21-day cycle

  • Dato-DXdDrug

    One IV infusion Q3W on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Dose-limiting Toxicities (Part 1 Dose Escalation)Time frame: Cycle 1 Day 1 up to Day 21 (each cycle is 21 days)
  2. Number of Participants Reporting Treatment-emergent Adverse Events (Part 1 Dose Escalation)Time frame: Screening up to 40 days after last dose, up to approximately 5 years
  3. Objective Response Rate Based on Investigator Assessment (Part 2 Dose Expansion)Time frame: Baseline (Screening), at every 6 weeks from Cycle 1 Day 1 in the first year, and every 12 weeks thereafter until disease progression or until the start of a new anticancer treatment, up to approximately 5 years

Locations

35 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope At Orange County Lennar Foundation Cancer Center

    Irvine, California

  • Sharp Memorial Hospital

    San Diego, California

  • Brcr Medical Center, Inc Dba Boca Raton Clinical Research

    Plantation, Florida

  • University of Hawaii At Manoa

    Honolulu, Hawaii

  • University of Chicago Medical Center

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Memorial Sloan-Kettering Cancer Center (Mskcc) - New York

    New York, New York

  • Clinical Research Alliance

    Westbury, New York

  • Unc Hospitals

    Chapel Hill, North Carolina

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • Mary Crowley Cancer Research Centers

    Dallas, Texas

  • Ut Southwestern Medical Center

    Dallas, Texas

  • University of Texas M. D. Anderson Cancer Center

    Houston, Texas

  • Next Virginia

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Peking University Third Hospital

    Beijing, China

  • Sun Yat-Sen University, Cancer Center

    Guangzhou, China

  • SunYat-Sen University Cancer Center

    Guangzhou, China

  • Harbin Medical Univeristy Cancer Hospital

    Heilongjiang, China

  • Hunan Cancer Hospital

    Hunan, China

  • Jilin Cancer Hospital

    Jilin City, China

  • Jinana Center Hosptial

    Shandong, China

  • IRCCS Istituto Scientifico Romagnolo Per

    Cesena, Italy

  • National Cancer Center Hospital

    Chūōku, Japan

  • National Hospital Org-Kyushu Cancer Center

    Fukuoka, Japan

  • National Cancer Center Hospital East

    Kashiwa, Japan

  • The Cancer Institute Hospital of Jfcr

    Kōtoku, Japan

  • Aichi Cancer Center Hospital

    Nagoya, Japan

  • Osaka International Cancer Institute

    Osaka, Japan

  • Kindai University Hospital

    Ōsaka-sayama, Japan

  • Shizuoka Cancer Center

    Shizuoka, Japan

  • Osaka University Hospital

    Suita, Japan

  • Kanagawa Cancer Center

    Yokohama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.